CJC-1295 and ipamorelin: what the pair does and what studies really show

CJC-1295 and ipamorelin are two different peptides, usually sold as a pair and often in the same vial, and no published trial has ever tested them together. Both make the pituitary gland release growth hormone, through different receptors. Each had a short run as a pharmaceutical candidate and was dropped before approval. Neither is FDA-approved, neither is on any list that lets pharmacies compound it, and vials labeled “for research use only” are not legal to use on people. If you came for one peptide on its own, the ipamorelin guide covers that side in depth, and this page carries the detail on CJC-1295 and on the pairing.

What is CJC-1295?

CJC-1295 is a lab-made version of growth hormone-releasing hormone, the brain’s signal telling the pituitary to release growth hormone. Natural GHRH is cleared from the blood quickly, which limits its use as a drug. CJC-1295 starts from the first 29 amino acids of GHRH, with four amino acids swapped to resist breakdown.

The version tested in people by its developer, the Montreal company ConjuChem, adds a DAC (drug affinity complex): a lysine linker carrying a reactive chemical that binds permanently to albumin, the main protein in blood. At least 90% of the injected peptide binds this way. In the 2006 study the estimated half-life was 5.8 to 8.1 days.

The version sold as “CJC-1295 without DAC”, also called modified GRF (1-29), is the same modified fragment without the albumin linker. We found no published human trial of this version, so nearly everything claimed about it is borrowed from the DAC version or from guesswork. That matters because the without-DAC form is the one most often paired with ipamorelin online. When FDA’s advisory committee reviewed CJC-1295 in December 2024, it voted on both forms.

What is ipamorelin?

Ipamorelin is a five-amino-acid peptide (a pentapeptide) developed at Novo Nordisk and described in 1998. It works on a different receptor: the ghrelin receptor, also called the growth hormone secretagogue receptor. Ghrelin is a hormone from the stomach that also triggers growth hormone release. In pigs, ipamorelin released growth hormone without raising the stress hormones ACTH and cortisol, even at doses more than 200 times the effective dose. In healthy men it had a half-life of about 2 hours.

Why are they sold together?

The pitch is that pressing two switches at once releases more growth hormone than pressing either alone. That is an extrapolation from physiology. We found no published human trial that tested CJC-1295 and ipamorelin together, measured the combined effect, or checked the safety of the pair.

There is also a mismatch at the center of the pairing. The tested CJC-1295 lasted about a week. The ipamorelin pulse was over within hours. The form usually paired, CJC-1295 without DAC, has no published human data at all, so the case for it is theory stacked on theory.

What the human studies found

IGF-1 (insulin-like growth factor 1) is the hormone the liver makes in response to growth hormone, and it carries many of growth hormone’s effects. None of these studies measured muscle, fat loss, sleep, recovery or any of the outcomes the pair is marketed for. They measured hormone levels, or, for ipamorelin, bowel recovery after surgery.

What results can you expect from CJC-1295 and ipamorelin?

Nobody knows, because no trial has measured a result a person would notice, on any timeline. Claims about leaner bodies at 12 weeks or better sleep in the first month come from clinics and forums. Higher hormone numbers are not the same as better outcomes. Growth hormone itself adds lean mass in fit adults without adding strength, as the guide to peptides for muscle growth shows.

The same goes for dosing. No human dose of either peptide has been established. The CJC-1295 and ipamorelin dosage page lists what the studies actually gave and why the daily schedules seen online do not follow from them.

Why development stopped

CJC-1295. ConjuChem’s phase 2 trial was testing 12 weeks of low-dose or high-dose CJC-1295 against placebo in people with HIV and excess visceral (deep belly) fat. In July 2006 the company halted dosing after a participant died at a clinical site in Argentina. The company said at the time that the cause of death and its relationship to the study drug were under investigation. The trial is listed as terminated, no later trial results for CJC-1295 have been published, and it never reached FDA approval.

Ipamorelin. Helsinn tested intravenous ipamorelin to speed recovery of bowel function after surgery. The first phase 2 trial found no significant difference from placebo on its key or secondary outcomes. A larger dose-finding trial finished in 2014 and has posted no results. Ipamorelin was never approved by FDA.

CJC-1295 and ipamorelin side effects

Short-term reactions are documented for each peptide alone. Nothing is documented for the pair, and no study has followed people on either for months.

FDA’s safety-risk page reports “serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction,” notes that clinical data are limited, and raises concerns about immune reactions. For ipamorelin it says a published study “identified serious adverse events including death when ipamorelin was administered intravenously.” That study was the bowel surgery trial: two people on ipamorelin died of complications after colon cancer surgery, and FDA said it is unclear whether the deaths were related to the drug.

Keep these in view too:

• Long-term effects are unknown. Prolonged high IGF-1 is a concern with approved growth hormone-releasing drugs: the tesamorelin label says the effects of prolonged IGF-1 elevation “are unknown” and tells prescribers to monitor it.
• Cancer history. Growth hormone and IGF-1 are growth factors. The approved drug in this class, tesamorelin, is contraindicated in active malignancy.
• Blood sugar and fluid. Growth hormone raises blood sugar and can cause fluid retention, joint pain and carpal tunnel symptoms, which the tesamorelin label lists.
• Pregnancy. Tesamorelin is contraindicated in pregnancy, and FDA notes animal data suggesting harm to fertility and fetal development from ghrelin itself.
• Two peptides in one vial. A reaction cannot be traced to one ingredient, and a blend cannot be adjusted one peptide at a time.

Get prompt medical care for hives, widespread rash or trouble breathing after an injection, for a severe headache with vision changes, or for unusual thirst and frequent urination. Tell the clinician exactly what you injected.

FDA status

Neither peptide is approved, and neither has a lawful route to compounding under section 503A, the part of federal law covering pharmacy compounding for individual patients.

If you have read that peptides became available again in October 2026, that does not apply here. As of November 2, 2026, HHS says it does not intend to take enforcement action over compounding of six named peptides, when each is compounded alone and other conditions are met. Neither CJC-1295 nor ipamorelin is one of the six, and the policy’s single-ingredient condition would rule out a two-peptide vial in any case.

The practical result: no pharmacy may lawfully compound either peptide under section 503A, and products sold as research chemicals are unapproved new drugs. Under 21 CFR 312.160, a company may ship an unapproved drug only for tests in laboratory animals or in test tubes, with a label reading “Not for use in humans.” FDA warning letters to peptide sellers, including one in March 2026, have found that the disclaimer does not protect a seller whose marketing shows the product is meant for people.

Are CJC-1295 and ipamorelin banned in sport?

Yes. Both are prohibited at all times under class S2 of the World Anti-Doping Agency’s Prohibited List. Section S2.2.4 names CJC-1295 as an example of a growth hormone-releasing hormone analogue (alongside sermorelin and tesamorelin) and ipamorelin as an example of a growth hormone secretagogue (alongside ibutamoren and macimorelin). The 2027 list, in effect January 1, 2027, keeps both entries.

How the pair compares with what is approved

The nearest approved drug is tesamorelin, which works on the same receptor as CJC-1295 and has phase 3 trials, a label and one approved use: reducing excess abdominal fat in HIV-associated lipodystrophy. The head-to-head framing in ipamorelin vs tesamorelin shows the gap in evidence. Sermorelin is the older GHRH fragment that was once an approved drug, and MK-677 is the oral drug that uses ipamorelin’s receptor.

Questions to ask a prescriber

No approved product exists for either peptide, so there is no labeled price or insurance route to compare. If a clinic offers this pair, ask:

• Which version of CJC-1295 is this, with or without DAC, and what human data support that version?
• Who made this product, and on what legal basis is it supplied, given that neither peptide is on the 503A bulks list?
• Has my growth hormone or IGF-1 been tested, and what would count as a result?
• What monitoring will you do for blood sugar, IGF-1 and side effects?
• Does my cancer history, diabetes risk or pregnancy plan change this?
• Is there an approved option for the problem I actually have?